These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33727289)

  • 1. Suvorexant improves intractable nocturnal enuresis by altering sleep architecture.
    Matsumoto T
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33727289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
    Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
    J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
    Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
    J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
    Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
    Svetnik V; Wang TC; Ceesay P; Snyder E; Ceren O; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D; Herring WJ
    J Sleep Res; 2021 Dec; 30(6):e13328. PubMed ID: 34340251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
    Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
    Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H
    J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
    Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.